Photosensitizers in clinical PDT.

By R. Allison, G. Downie, R. Cuenca, Xingen Hu, C. Childs, C. Sibata. Photodiagnosis and Photodynamic Therapy, 2004

914 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Photodynamic Therapy in Dentistry (2007, background): “Large multi-institutional studies with appropriate dosimetric considerations and unbiased interpretation of results are nevertheless required, to verify the potential of targeted PDT (Allison et al., 2004a).”
Photophysics and photochemistry of photodynamic therapy: fundamental aspects (2009, background): “, surgery, radiation therapy or chemotherapy [58].”
Oncologic photodynamic therapy photosensitizers: a clinical review. (2010, background): “[40] Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJH, Sibata CH.”
Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications. (2005, background): “For a photosensitizer to be clinically useful it should be non-toxic, selectively taken up and/or retained in malignant tissue, activated by penetrating light (>600 nm), and relatively photochemically efficient [1, 13 ].”
Biodegradable black phosphorus-based nanospheres for in vivo photothermal cancer therapy (2016, background): “Even if the NSs-treated mice are under artiﬁcial daylight illumination for 24 h, no signiﬁcant toxic side effects can be found, indicating that the NSs induce no evident phototoxicity which has generally been observed from many photosensitizer molecules 60 .”